» Articles » PMID: 38472674

Higher Postoperative Mortality and Inferior Survival After Right-Sided Liver Resection for Perihilar Cholangiocarcinoma: Left-Sided Resection is Preferred When Possible

Abstract

Background: A right- or left-sided liver resection can be considered in about half of patients with perihilar cholangiocarcinoma (pCCA), depending on tumor location and vascular involvement. This study compared postoperative mortality and long-term survival of right- versus left-sided liver resections for pCCA.

Methods: Patients who underwent major liver resection for pCCA at 25 Western centers were stratified according to the type of hepatectomy-left, extended left, right, and extended right. The primary outcomes were 90-day mortality and overall survival (OS).

Results: Between 2000 and 2022, 1701 patients underwent major liver resection for pCCA. The 90-day mortality was 9% after left-sided and 18% after right-sided liver resection (p < 0.001). The 90-day mortality rates were 8% (44/540) after left, 11% (29/276) after extended left, 17% (51/309) after right, and 19% (108/576) after extended right hepatectomy (p < 0.001). Median OS was 30 months (95% confidence interval [CI] 27-34) after left and 23 months (95% CI 20-25) after right liver resection (p < 0.001), and 33 months (95% CI 28-38), 27 months (95% CI 23-32), 25 months (95% CI 21-30), and 21 months (95% CI 18-24) after left, extended left, right, and extended right hepatectomy, respectively (p < 0.001). A left-sided resection was an independent favorable prognostic factor for both 90-day mortality and OS compared with right-sided resection, with similar results after excluding 90-day fatalities.

Conclusions: A left or extended left hepatectomy is associated with a lower 90-day mortality and superior OS compared with an (extended) right hepatectomy for pCCA. When both a left and right liver resection are feasible, a left-sided liver resection is preferred.

Citing Articles

Improved Outcomes Following Resection of Perihilar Cholangiocarcinoma: A 27-Year Experience.

Jain A, Lendoire M, Haddad A, Tzeng C, Boyev A, Maki H Ann Surg Oncol. 2025; .

PMID: 40000564 DOI: 10.1245/s10434-025-17075-5.


Preoperative factors predicting outcomes in patients with suspected perihilar cholangiocarcinoma referred for curative resection- a single-center 10-year experience.

Al-Saffar H, Larsen P, Schultz N, Kristensen T, Renteria D, Knofler L Langenbecks Arch Surg. 2024; 410(1):13.

PMID: 39708095 DOI: 10.1007/s00423-024-03583-7.


Major Hepatectomy for Perihilar Cholangiocarcinoma: Taking Sides.

Soreide K Ann Surg Oncol. 2024; 31(7):4169-4172.

PMID: 38517613 DOI: 10.1245/s10434-024-15211-1.

References
1.
van Keulen A, Franssen S, van der Geest L, de Boer M, Coenraad M, van Driel L . Nationwide treatment and outcomes of perihilar cholangiocarcinoma. Liver Int. 2021; 41(8):1945-1953. PMC: 8359996. DOI: 10.1111/liv.14856. View

2.
Buettner S, van Vugt J, Gani F, Groot Koerkamp B, Margonis G, Ethun C . A Comparison of Prognostic Schemes for Perihilar Cholangiocarcinoma. J Gastrointest Surg. 2016; 20(10):1716-24. PMC: 5450027. DOI: 10.1007/s11605-016-3203-2. View

3.
Koerkamp B, Wiggers J, Gonen M, Doussot A, Allen P, Besselink M . Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram. Ann Oncol. 2015; 26(9):1930-1935. PMC: 4754626. DOI: 10.1093/annonc/mdv279. View

4.
Mosconi C, Renzulli M, Giampalma E, Galuppi A, Balacchi C, Brandi G . Unresectable perihilar cholangiocarcinoma: multimodal palliative treatment. Anticancer Res. 2013; 33(6):2747-53. View

5.
Gaspersz M, Buettner S, van Vugt J, Roos E, Coelen R, Vugts J . Conditional survival in patients with unresectable perihilar cholangiocarcinoma. HPB (Oxford). 2017; 19(11):966-971. DOI: 10.1016/j.hpb.2017.07.004. View